ARTICLE | Emerging Company Profile
MoonLake: IL-17 advances in a Nanobody package
Awaiting a SPAC, the Swiss company thinks it can bring more efficacy, safety to IL-17-driven diseases
October 27, 2021 4:48 AM UTC
MoonLake thinks its trispecific Nanobody will translate growing understanding of IL-17 biology into a treatment with improved efficacy and safety for inflammatory diseases of the joints and skin.
The Swiss company, which launched in May with a license to the Phase II-stage sonelokimab from Merck KGaA (Xetra:MRK) and a series A round from the pharma and BVF Partners, announced Oct. 8 that it will go public via a SPAC merger that is expected to complete late 4Q21 or early 1Q22...